The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy

International Journal of Biological Markers

Volumn 22, Issue 1 SUPPL. 4, 2007, Pages

  Tortora, Giampaolo ^a   Gelardi, T ^a   Ciardiello, F ^b   Bianco, R ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Combined therapy; EGFR; Target therapy

Indexed keywords

CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CHEMOSENSITIZATION; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CROSS RESISTANCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION REGULATION; HEAD AND NECK CARCINOMA; HUMAN; INTERMETHOD COMPARISON; IONIZING RADIATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NONHUMAN; OPTIMAL DRUG DOSE; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

EID: 34248334117     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/jbm.2008.3794     Document Type: Article

References (29)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
2. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16.
3. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
4. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-32.
5. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 369-85.
6. Ryan PD, Chabner BA. On receptor inhibitors and chemotherapy. Clin Cancer Res 2000; 6: 4607-9.
7. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85: 1327-33.
8. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994; 269: 27595-602.
9. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996; 19: 419-27.
10. Ciardiello F, Bianco R, DamianoV, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5: 909-16.
11. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6: 1936-48.
12. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003; 39: 1-16.
13. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120: 781-7.
14. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol 2005; 76: 157-61.
15. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-40.
16. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000; 18: 47S-53S.
17. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999; 14: 451-63.
18. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701-8.
19. Nasu S, Ang KK, Fan Z, Milas L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001; 51: 474-7.
20. Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002; 54: 1180-93.
21. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637-42.
22. Karashima T, Sweeney P, Slaton JW, et al. Inhibition of angiogenesis by the anti epidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002; 8: 1253-64.
23. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8: 994-1003.
24. Salazar R, Tabernero J, Rojo F, et al. Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (Mab) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmcodynamic (PK/PD) study to define the optimal biological dose (OBD). Proc Am Soc Clin Oncol 2004; Abstract 2002.
25. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23.
26. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999; 59: 1236-43.
27. Di Gennaro E, Barbarino M, Bruzzese F, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD 1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003; 1: 139-50.
28. Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001; 61: 5790-5.
29. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drug activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-63.